Skye is planning to initiate a Phase 2b clinical trial in obesity for nimacimab with ENHANZE in the middle of 2026. This study will also assess the combination of nimacimab and a GLP-1R agonist.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback